Corcept Therapeutics (CORT) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed Corcept Therapeutics (CORT) over the past year, gaining 115.2% versus a gain of 32.4%. Over five years, CORT leads with a +496.8% price change compared with +355.0% for PTGX. Corcept Therapeutics is the larger company by market cap ($12.93 billion vs $9.12 billion), about 1.4 times the size.
On valuation, Protagonist Therapeutics trades at a lower trailing P/E (136.8x vs 265.8x for Corcept Therapeutics). Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CORT | PTGX |
|---|---|---|
| Share price | $119.60 | $140.92 |
| Market cap | $12.93B | $9.12B |
| 1-day change | +0.03% | +1.61% |
| YTD return | +243.68% | +61.35% |
| 1-year return | +32.42% | +115.24% |
| 5-year return | +496.81% | +355.02% |
| P/E ratio (TTM) | 265.78 | 136.82 |
| Forward P/E | 27.17 | — |
| EPS (TTM) | $0.45 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $761.41M | $46.02M |
| Revenue growth (YoY) | +12.79% | -89.41% |
| Net income (latest FY) | $99.65M | $-130.15M |
| Gross margin | 98.30% | — |
| Operating margin | 5.88% | -343.63% |
| Net margin | 13.09% | -282.83% |
| 52-week high | $126.38 | $160.81 |
| 52-week low | $28.66 | $65.56 |
| Distance from 52-week high | -5.36% | -12.37% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +17.89% | +23.96% |
| Average volume | 1.30M | 632.64K |
| Shares outstanding | 108.10M | 64.71M |
| Employees | 730 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed CORT by 82.8 percentage points over the past year.
- Corcept Therapeutics trades at a higher earnings multiple (265.8x vs 136.8x trailing P/E).
- Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- Corcept Therapeutics grew revenue faster in its latest fiscal year (+12.79% vs -89.41%).
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
CORT vs PTGX FAQ
Which is bigger, Corcept Therapeutics or Protagonist Therapeutics?
Corcept Therapeutics (CORT) is larger, with a market capitalization of $12.93B compared with $9.12B for Protagonist Therapeutics (PTGX).
Which stock has performed better over the past year, CORT or PTGX?
PTGX returned +115.24% over the past 12 months, compared with +32.42% for CORT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CORT or PTGX?
PTGX has the lower trailing P/E at 136.8, versus 265.8 for CORT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Corcept Therapeutics and Protagonist Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.